<DOC>
	<DOCNO>NCT02889315</DOCNO>
	<brief_summary>Subcutaneous treprostinil use treat pulmonary arterial hypertension ( PAH ) . Due local pain cause deterioration quality life even abandonment treatment . The aim study evaluate safety quality life ( QoL ) patient treat treprostinil administration use implantable Lenus Pro® pump . This observational study involve patient PAH treat subcutaneous infusion treprostinil intolerable pain infusion site , therefore refer pump implantation . Clinical evaluation , include QoL assessment SF-36 questionnaire perform time initiate therapy treprostinil , 2-9 month implantation .</brief_summary>
	<brief_title>LenusPro Pump PAH Treated With Treprostinil</brief_title>
	<detailed_description>Treprostinil prostacyclin analogue , drug widely use treat pulmonary arterial hypertension ( PAH ) . Its efficacy confirm study compare placebo epoprostenol . Due stability treprostinil sodium solution relatively long ( compare prostacyclin ) half-life , drug enable PAH patient receive safe long-term treatment . It administer continuous subcutaneous infusion use insulin pump . In case route administration , half-life 3 hour . Unfortunately , due reaction infusion site many patient report significant deterioration quality life , ( 5-10 % ) even abandon treatment . There trial progress find convenient method administration drug . The efficacy oral administration uncertain - report contradictory , inhalation remain valid alternative patient less advanced stage disease . Therefore , patient whose illness severe , continuous parenteral administration drug remain option . The Lenus Pro® implantable pump appear promising alternative external pump . By mean method , treprostinil sodium administer continuous intravenous infusion , drug reservoir refill every 28 day . Thermal stability treprostinil body temperature confirm 60-day observation ; concentration drug administer intravenously comparable subcutaneous administration , differ parameter short half-life less 1 hour . The first experience implantable pump originate Austria Germany present method treatment milestone PAH therapy . In Poland , first implantation Lenus Pro® pump take place 2013 ( 18 ) . The aim study analysis efficacy safety treatment intravenous treprostinil administer mean Lenus Pro® implantable pump . Prior pump implantation subcutaneous dose treprostinil escalate high dose tolerate particular patient . The procedure pump implantation carry general anaesthesia Clinical haemodynamic evaluation perform time initiate PAH therapy treprostinil . Right 2-9 month Lenus Pro® pump implantation , non-invasive clinical evaluation make , include : WHO functional class , 6-minute walk test ( 6MWT ) , concentration NT-proBNP . Additionally patient fill SF36 quality life questionnaire implantation 2-9 month implantation .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>diagnose Pulmonary Arterial Hypertnesion accord ESC/ERS Guidelines treatment sc treprostinil stable dose poor local tolerance sc infusion life expectancy &lt; 6 month age &lt; 18 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>PAH</keyword>
	<keyword>treprostinil</keyword>
	<keyword>LenusPro</keyword>
	<keyword>implantable device</keyword>
	<keyword>quality life</keyword>
</DOC>